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Abstract
To identify new compounds with anti-human cytomegalovirus (HCMV) activity and new anti-HCMV targets, we developed a high-
throughput strategy to screen a GlaxoSmithKline Published Kinase Inhibitor Set. This collection contains a range of extensively
characterized compounds grouped into chemical families (chemotypes). From our screen, we identified compounds within
chemotypes that impede HCMV protein production and identified kinase proteins associated with inhibition of HCMV protein
production that are potential novel anti-HCMV targets. We focused our study on a top ‘hit’ in our screen, SB-734117, which we
found inhibits productive replication of several HCMV strains. Kinase selectivity data indicated that SB-734117 exhibited
polypharmacology and was an inhibitor of several proteins from the AGC and CMCG kinase groups. Using Western blotting, we
found that SB-734711 inhibited accumulation of HCMV immediate-early proteins, phosphorylation of cellular proteins involved
in immediate-early protein production (cAMP response element-binding protein and histone H3) and histone H3 lysine 36
trimethylation (H3K36me3). Therefore, we identified SB-734117 as a novel anti-HCMV compound and found that inhibition of
AGC and CMCG kinase proteins during productive HCMV replication was associated with inhibition of viral protein production
and prevented post-translational modification of cellular factors associated with viral protein production.
INTRODUCTION
Disease associated with human cytomegalovirus (HCMV)
infection affects a range of immunodeficient individuals [1].
As yet, there is no widely available vaccine against HCMV [2],
and disease management largely rests on the use of anti-
HCMV drugs [1, 3]. The most widely used anti-HCMV drugs
[including the frontline drug ganciclovir (GCV)] target the
viral DNA polymerase, thereby inhibiting HCMV replication
[3]. However, there are drawbacks to the use of GCV and
other currently available anti-HCMV drugs, including the
development of drug-resistant virus [3]. Furthermore, HCMV
not only undergoes productive replication but can also enter a
latent state from which the virus can reactivate. Currently,
there is no effective treatment to clear latent HCMV infection.
Several novel anti-HCMV drugs are under development [1,
3, 4]. One strategy to expand the range of anti-HCMV drugs
available is to identify existing compounds with hitherto
unappreciated anti-HCMV activity. A large number of cur-
rently available compounds inhibit protein kinases in each
of the groups that comprise the human kinome. Protein
kinases are involved in many aspects of HCMV replication
and pathogenesis, including intracellular signalling that
results in transcription from the HCMV major immediate-
early promoter (MIEP), which stimulates a transcriptional
cascade (immediate-early to early to late gene transcription)
required for productive HCMV replication and reactivation
from latency [1]. Therefore, protein kinase inhibitors could
inhibit productive HCMV replication or reactivation from
latency, and a number of kinase inhibitors with anti-HCMV
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activity have been identified [3]. Furthermore, it is possible
that the full complement of protein kinases that are required
for HCMV replication has yet to be identified. Therefore,
kinase inhibitors could be used as chemical probes to iden-
tify kinase proteins required for HCMV replication, many
of which could be novel anti-HCMV drug targets. However,
an important consideration when using kinase inhibitors is
that compounds targeting the conserved ATP-binding site
of a kinase protein can display polypharmacology and are
capable of inhibiting several kinase proteins or proteins out-
side the kinome, such as G-protein-coupled receptors
(GPCRs) [5–7]. Therefore, knowledge of kinase selectivity is
important when discussing the use of kinase inhibitors as
drugs or chemical probes [5].
We utilized a high-throughput screening methodology to
assess the ability of compounds within a GlaxoSmithKline
published kinase inhibitor set (GSK PKIS) [8] to inhibit
HCMV protein production. This compound library con-
tained a range of extensively characterized compounds
organized into structurally related collections of compound
families (chemotypes) [7, 8]. Known characteristics of com-
pounds within this GSK PKIS collection include kinase
selectivity, compound structures and off-targets effects.
Therefore, screening of this compound library allowed iden-
tification of both compounds and chemotypes with anti-
HCMV activity, identification of novel anti-HCMV drug
targets and permitted the on- and off-target effects of com-
pounds identified in the screening process to be considered.
These data lead to investigation of the anti-HCMV activity
of a top ‘hit’ in our screen, SB-734117.
RESULTS
High-throughput screening of a GSK PKIS library to
identify protein kinase inhibitors with anti-HCMV
activity
To identify compounds with anti-HCMV activity, we utilized
a high-throughput screening methodology (Fig. 1a), similar to
the approach that we have previously used to screen small
interfering RNAs in HCMV-infected cells [9]. Briefly, high-
passage HCMV strain AD169 and compounds from the GSK
PIKS collection (listed in Table S1, available in the online Sup-
plementary Material) were added to duplicate 384-well plates
seeded with human foreskin fibroblast (HFF) cells. As negative
and positive controls for compound treatment, several wells in
each plate were treated with either DMSO or heparan sulphate
(a small molecule that inhibits HCMV entry into cells) [10],
respectively. At 72 h post-infection (p.i.), cells were stained
with Hoechst 33342 to detect nuclear DNA and CellMask to
detect the area of the cell, and were treated with antibodies to
detect the cytoplasmic HCMV antigen pp28. An automated
microscopy system was then used to assay both the number of
cells in each well and the number of infected cells in each well
expressing pp28. An image of infected cells treated as
described above and captured using automated microscopy is
shown in Fig. 1(b).
The mean number of cells in each well per plate was deter-
mined. Where the number of cells in any well was less than
two-fold below the mean number of cells of the plate, the
compound in that well was judged to be cytotoxic (listed by
chemotype in Table 1 and by compound in Table S2). Data
from the remaining wells on duplicate plates were combined
and converted to a Z-score (the number of standard devia-
tions from the mean of the data) [11, 12] to demonstrate
the increase (positive Z-score) or decrease (negative Z-
score) in the number of pp28 positive cells in the presence
of each compound [shown in Fig. 1(c), listed by chemotype
in Table 1 and by compound in Table S3].
Analysis of cytotoxic compounds
We first investigated what compounds within chemotypes
were judged to be cytotoxic. Approximately 40–50% of
compounds in the benzimidazole N-thiophene, 2H-3 pyri-
midinyl pyrazolopyridazine, 3-amino pyrazolopyridine and
6-phenyl isoquinoline chemotypes contained compounds
judged to be cytotoxic to HCMV-infected cells (Tables 1
and S2). Therefore, compounds from these chemotypes are,
generally, not suitable for further use.
We then utilized kinase selectivity data to investigate
which kinase proteins were inhibited by each compound
judged to be cytotoxic (Table S4). Kinase selectivity data
[7] lists the ability of each compound to inhibit a panel of
224 kinase proteins from several protein groups of the
human kinome [including TK (tyrosine kinase), STE
(homologues of yeast Sterile 7, Sterile 11, Sterile 20 kin-
ases), AGC (containing PKA, PKG, PKC families), S-T-PK
(serine/threonine protein kinase), CAMK (calcium/cal-
modulin-dependent protein kinase) and CMCG (contain-
ing CDK, MAPK, GSK3, CLK families) groups]. We
found that all cytotoxic benzimidazole N-thiophenes were
potent inhibitors of PLK-1 (polo-like kinase 1), whose
inhibition can lead to apoptosis, and nearly all other cyto-
toxic compounds from a number of chemotypes were
potent inhibitors of a range of CDK (cyclin-dependent
kinase) proteins, which are involved in regulation of the
cell cycle. In our screen cytotoxicity was judged by the
number of cells detected in each well of the screening
plate. Therefore, we concluded that compounds were gen-
erally judged to be cytotoxic due to apoptosis associated
with inhibition of PLK-1 or due to lack of cell division
associated with inhibition of CDK function.
Analysis of compounds with assigned Z-scores
Next, we analysed those compounds with assigned Z-scores
to determine which compounds and chemotypes should be
considered for further study as anti-HCMV compounds
and chemical probes. We found that nearly all chemotypes
contained compounds that had both positive and negative
effects on pp28 production. Notably, however, the 2-aryl 3-
pyridimidinyl pyrazolopyridazine and furopyrimidine che-
motypes and the 3-vinyl pyridine, 2,4-diamino pyrimidine,
maleimide, phenyl carboxamide and indazole-5-carboxa-
mide chemotypes contained a large number of compounds
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Fig. 1. High-throughput screening of the PKIS collection. (a) Diagram of the screening process. (b) A representative example of a
microscopy image from an Image Express Micro microscope of infected HFF cells treated with Hoechst 33342 (blue), Deep Red Cell
Mask (red) and primary and secondary antibodies to detect HCMV pp28 (green). The large white box is a magnified image of the area
identified by the small white box. (c) Plot of Z-scores where each data point represents a single compound. The compounds with high-
est and lowest Z-scores are identified, and their Z-scores are stated in parentheses. (d) Structures of compounds with Z-scores (i–iv)
lower than  2 and (v–vii) greater than 2.
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with negative and positive effects on pp28 production,
respectively (Tables 1 and S3). We sought to further charac-
terize the results of our screen and judged any compound
with a Z-score between 1 and  1 to have little or no effect
on pp28 production, whereas compounds with Z-scores of
 1 to  2 and 1 to 2 had modest negative or positive effects
on pp28 production, respectively. Thus, compounds with Z-
scores of less than  2 or more than 2 had the greatest nega-
tive or positive effect on pp28 production, respectively.
Therefore, three compounds (GW575808A, GW874091X
and GW627512B) from three different chemotypes (2,4-
diamino pyrimidines, imidazotriazines and 2-amino oxa-
zoles, respectively) had strong positive effects on pp28
production, while four compounds (GW297361X, SB-
734117, SB-220025-R and GW795493X) from four chemo-
types (oxindoles, furazan benzimidazoles, 4-pyrimidinyl
ortho-aryl azoles and furopyrimidines, respectively) had
strong negative effects on pp28 production (Fig. 1c, d).
Examination of kinase protein inhibition by
compounds with assigned Z-scores
We then examined kinase selectivity data of compounds
with assigned Z-scores (Table S5). The data from Table S5
are presented in Fig. 2 as a ‘heatmap’ of kinase inhibition.
Nearly all compounds with assigned Z-scores exhibited
polypharmacology and could inhibit more than one kinase
protein. Consistent with our analysis of compounds judged
to be cytotoxic (Table S2), we found that less than 5% of all
compounds either potently inhibited PLK-1 or were potent
inhibitors of several different CDK proteins (Table S5).
Compounds with positive or negative Z-scores were
inhibitors of a wide range of kinase proteins in the TK group
(Fig. 2 and Table S5). Therefore, inhibition of TK proteins
alone was unlikely to positivity or negatively influence pp28
production. However, a number of kinases in the STE
[including MAP4K4 (mitogen-activated protein kinase
kinase kinase kinase 4) and MNK (MAP kinase-interacting
serine/threonine-protein kinase)], CAMK [including PRKD1
Table 1. Results of screening listed by chemotype
Chemotype Total no. compounds
in chemotype
No. compounds excluded
due to cytotoxicity
No. compounds with
assigned Z-scores
4-Pyrimidinyl ortho-aryl azoles 31 0 31
Oxindoles 30 3 27
Furazan benzimidazoles 25 1 24
4-Anilino quinazolines and related 25 0 25
Benzimidazole N-thiophenes 21 9 12
4-Pyridyl ortho-aryl azoles 18 0 18
2H-3 Pyrimidinyl pyrazolopyridazines 16 7 9
2-Amino oxazoles 15 0 15
4-Hydrazinyl pyrazolopyrimidines 15 0 15
2,4-Dianilino pyrrolopyrimidines 15 1 14
Biaryl amides 14 0 14
3-Vinyl pyridines 13 0 13
Anilino thienopyrimidines 12 0 12
Benzimidazolyl diaryl ureas 12 2 10
2-Aryl 3-pyridimidinyl pyrazolopyridazines 12 0 12
2,4-Diamino pyrimidines 12 0 12
Maleimide 11 0 11
Furopyrimidines and related 9 0 9
Indazole-3-carboxamides 7 1 6
3-Amino pyrazolopyridines 7 3 4
2-Pyridinyl imidazoles and related 7 0 7
4-Anilino 5-alkynyl pyrimidines 7 0 7
3-Cyano thiophenes 6 2 4
Phenyl carboxamides 6 0 6
Indazole-5-carboxamides 6 0 6
3-Amino pyrazolopyridazines 4 1 3
3-Amino pyrazoles 3 0 3
Imidazotriazine 3 0 3
4-Anilino quinolones 2 0 2
6-Phenyl isoquinolines 2 1 1
3-Benzyl pyrimidines 1 0 1
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Fig. 2. Kinase selectivity of compounds with assigned Z-scores. The full list of kinase selectivity data is shown in Table S5. Table S5
is shown here as a ‘heatmap’ of kinase selectivity wherein the potency of each compound at 1 µM concentration against a particular
kinase is represented in colour as indicated at the bottom of the figure (less than 0% inhibition, blue; 0–50% inhibition, green; 51–
75% inhibition, yellow; 76–90% inhibition, orange; greater than 91% inhibition, red). Each row represents a compound, and each col-
umn represents the kinase tested. The Z-scores of each compound are indicated to the left of the figure. The kinase groups of each
kinase tested are indicated above the figure. (a–c) Kinase inhibition of compounds with Z-scores of less than  1 not found in com-
pounds with Z-scores greater than 1. (d) Kinase inhibition of compounds with Z-scores greater than 1 not found in compounds with Z-
scores of less than  1.
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(protein kinase D1), PRKD2 and PRKD3] and CMCG
[including CLK2 (cyclin-dependent kinase-like kinase 2),
HIPK1 (homeodomain-interacting protein kinase 1), HIPK4,
DYRK1A (dual-specificity tyrosine phosphorylation-regu-
lated kinase 1A), DYRK1B, DYRK2] groups were inhibited
by compounds with assigned Z-scores of less than  1 from
eight, four and three different chemotypes, respectively
(Fig. 2a–c, respectively, and Table S5). Therefore, these
kinase proteins, alone or in combination, were likely to be
important for HCMV replication and could represent future
anti-HCMV drug targets. A number of compounds from
two different chemotypes that inhibited kinases in AGC
kinase family [including PRKG1 (protein kinase, cGMP
dependent 1), PRKG2, PRKX (protein kinase, x-linked),
PKA, ROCK1 (rho-associated, coiled-coil-containing protein
kinase 1), ROCK2] were assigned Z-scores over 1 (Fig. 2d).
Therefore, these kinase proteins, alone or in combination,
were likely to be inhibitory to HCMV replication. Com-
pounds targeting these kinase proteins are likely to be of lit-
tle value as anti-HCMV drugs.
Compounds with assigned Z-scores of less than  2
(GW297361X, SB-734117, SB-220025-R and GW795493X)
each had a different kinase selectivity profile (Fig. 2 and
Table S5). Therefore, it was likely each compound inhibited
pp28 production by a different mechanism. Each was a
potent inhibitor of several kinase proteins from several
groups, except for SB-220025-R, which was a potent inhibi-
tor of only two kinase proteins: CK1a (casein kinase 1a) and
p38a (Fig. 2 and Table S5).
Kinase inhibition of compounds with assigned Z-scores of
greater than 2 was also examined. GW575808A and
GW627512B had similar kinase selectivity profiles and were
inhibitors of several TK and S-T-PK group kinases (Fig. 2
and Table S5). As inhibition of these TKs and S-T-PKs can
result in either positive or negative Z-scores (Fig. 2 and
Table S5), it was unlikely that inhibition of these TK and S-
T-PK proteins had a direct effect on pp28 production.
Moreover, we found that GW874091X was not a potent
inhibitor of any kinase assayed (Fig. 2 and Table S5). There-
fore, GW874091X was either an inhibitor of kinase proteins
not assayed in the kinase selectivity data or exerted an effect
on pp28 production that did not involve inhibition of cellu-
lar kinase proteins. It therefore remains unclear from this
analysis which kinase proteins should not be targeted in the
development of future anti-HCMV drugs.
We further considered the polypharmacology of compounds
tested in our screen. It has been reported that ATP-competi-
tive kinase inhibitors can inhibit the function of proteins
other than kinases, including aminergic GPCRs [6]. GPCR
agonism and antagonism of the compounds in the GSK
PKIS collection has been investigated elsewhere [7]. No
compound within the GSK PKIS collection is a GPCR ago-
nist, but several are GPCR antagonists [7]. However, we
observed no obvious correlation between compounds
judged to be cytotoxic, compounds assigned a Z-score and
GPCR antagonism (data not shown).
Inhibition of HCMV replication by SB-734117
We chose to focus our studies on SB-734117, a compound
from the furazan benzimidazole chemotype that had a low
Z-score in our screen (Fig. 1c, d). First, we used viral yield
reduction assays to assess the ability of SB-734117 to inhibit
replication of HCMV strain AD169 compared to the front-
line anti-HCMV drug GCV (Table 2, experiment 1) at up to
96 h p.i. The ED50 of both SB-734117 and GCV was 0.5 µM,
indicating that SB-734117 inhibited AD169 replication as
efficiently as the current frontline anti-HCMV drug. To
complement and confirm this data, we analysed AD169 rep-
lication over time and found an approximately twofold
decrease in AD169 replication from 72–96 h p.i. in the pres-
ence of 1 µM SB-734117 (Fig. 3a).
We also found that SB-734117 could inhibit replication of a
GCV-resistant virus (AD169-P53) and a low-passage
HCMV strain [Merlin(RCMVR1111)], whose genomic con-
tent is similar to a clinical sample [13], at low or sub-
micromolar ED50 values (Table 2, experiments 2 and 3,
respectively) at up to 96 h p.i. Therefore, SB-734117 was an
effective inhibitor of different HCMV strains.
To ensure that the anti-HCMV activity of SB-734117 was
not due to cellular cytotoxicity, we used an MTT dye-uptake
assay to assess cell viability and cell division in uninfected
cells in the presence of SB-734117. We found that the 50%
cellular cytotoxicity of SB-734117 after 96 h treatment with
SB-734117 was greater than 10 µM (data not shown). Thus,
the 50% cellular cytotoxicity values in uninfected cells were
greater than 10 µM at the ED50 values for all HCMV strains
tested. Therefore, inhibition of HCMV replication by SB-
734117 observed in experiments shown in Table 2, or in the
other experiments presented here, was unlikely to be the
result of cellular cytotoxicity or inhibition of cell division.
Examination of HCMV immediate-early protein and
mRNA production in HCMV-infected cells treated
with SB-734117
We next sought to understand how HCMV replication was
inhibited by SB-734117. Therefore, western blotting was used
to analyse the accumulation of HCMV proteins in the pres-
ence or absence of SB-734117 (Fig. 3b). Compared to treat-
ment of infected cells with DMSO (Fig. 3b, lanes 2–4), the
treatment of infected cells with SB-734117 (Fig. 3b, lanes 5–7)
reduced the accumulation of immediate-early proteins IE1
and IE2, and IE2 proteins expressed late in infection (IE2-60
and IE2-40) [14]. In this and subsequent western blots, the
amount of b-actin in each sample was also assayed, which
demonstrated equivalent loading of samples in each lane.
We then quantified the relative density of the Western blot-
ting bands shown in Fig. 3(b), by determining the intensity
of bands corresponding to viral proteins relative to the
intensity of the b-actin band in the same lane (Fig. 3c). We
found an approximately two- to fourfold decrease in the
accumulation of IE1 in the presence of 1 µM SB-734117,
which is consistent with an ED50 of 0.5–1 µM shown in
Table 2. The loss of IE2 protein production (approximately
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2- to 20-fold, depending on which antibody was used
Fig. 3c) was greater than IE1. Consistent with loss of IE pro-
tein production and our screening results, we also observed
using western blotting that treatment of cells with SB-
734117 resulted reduced accumulation of the HCMV early
and late proteins UL44 and pp28, respectively, compared to
infected cells treated with DMSO (data not shown). To
complement these findings, we assayed for differences in
IE1 and IE2 mRNA expression in infected cells treated with
SB-734117 compared to infected cells treated with DMSO
using quantitative PCR against the two major IE RNA spe-
cies (Fig. 3d). This analysis revealed that no obvious defect
in IE1 mRNA levels was evident in the presence of SB-
734117. The analysis of IE2 mRNA again did not show any
overt phenotype, although typically a twofold reduction in
IE2 mRNA was observed in SB-734117-treated cells when
compared with DMSO control. However, taken together,
the data suggest that the decrease in IE1 and IE2 protein
production shown in Fig. 3(b, c) was unlikely to be the
result of decreased IE gene expression alone.
Our studies thus far could not rule out that SB-734117
impacted events occurring prior to IE gene expression.
Thus, we addressed whether the presence of SB-734117 may
affect virus entry into the cell or translocation of the HCMV
genome to the nucleus. Pre-exposure of cells to SB-734117
before infection or incubation of virus with SB-734117
before infection did not increase the inhibitory effects of the
compound (data not shown). However, when we treated
AD169-infected HFF cells with 1 µM SB-734117 at 24 h p.i.,
we found a two-fold decrease in HCMV replication at 120
h p.i., compared to infected cells treated with DMSO at 24 h
p.i. (Fig. 4a). Quantitative analysis of Western blotting of
infected cells treated as described above (Fig. 4a, b) showed
that, similar to data presented in Fig. 3, treatment of
infected cells with SB-734117 resulted in approximately
two-fold decrease in IE2 protein production depending on
which antibody was used. However, there was no obvious
decrease in production of IE1 protein.
Therefore, SB-734117 had no obvious effect on cells or virus
before infection but could inhibit HCMV replication after
entry of the HCMV genome and did so by reducing IE pro-
tein production. Thus, SB-734117 may not inhibit events
during infection before expression of IE proteins, but could
have inhibitory effects on HCMV replication after the
initiation of IE protein production.
Inhibition of AGC and CMCG kinase proteins by SB-
734711
Next, we investigated what kinase proteins are inhibited by
SB-734117. SB-734117 has been reported to inhibit MSK1
(mitogen and stress kinase 1) [15]. However, using the
kinase selectivity data shown in Fig. 2 and Table S5, we
found that SB-734117 inhibits several AGC kinase group
proteins, including MSK1 [MSK1, MSK2, RSK1 (ribosomal
s6 kinase 1), RSK2, RSK3, p70S6K1, PKC-h (protein kinase
C-h), PRKG2, ROCK1, ROCK2] and several CMCG kinase
group proteins (GSK3A, GSK3B, DYRK1A and DYRK1B).
However, in our screen, potent and selective inhibitors of
GSK3A and GSK3B had no obvious negative effect on pp28
production (Table S5), and compounds with either positive
or negative Z-scores were potent inhibitors of PKC-h,
PRKG2, ROCK1 and ROCK2 (Table S5). Therefore,
inhibition of these kinase proteins may not be related to
inhibition of pp28 production. Rather, analysis of SB-
734117 kinase selectivity data compared to other assigned
Z-scores argued that potent inhibition of MSK1, MSK2,
RSK1, RSK2, RSK3, p70S6K1, DYRK1A and DYRK1B was
related to inhibition of pp28 production.
A kinase inhibitor that is structurally unrelated to SB-
734117, H-89, inhibits a similar range of AGC and CMCG
kinase proteins [16]. We found that H-89 inhibited
productive HCMV replication and immediate-early protein
production (data not shown). Therefore, inhibition of AGC
and CMCG kinase proteins, not an unknown function of
SB-734117, is likely to be responsible for the observed
defects in HCMV replication and protein production. Fur-
thermore, using western blotting [17], we found that
SB-734117 did not inhibit autophosphorylation of the
HCMV-encoded kinase UL97 (data not shown). Therefore,
the anti-HCMV effects of SB-734117 were unlikely to be
due to inhibition of UL97.
Analysis of cAMP response element-binding
protein and histone H3 phosphorylation in HCMV-
infected cells
We then considered how inhibition of AGC and CMCG
kinase proteins by SB-734114 would affect post-transla-
tional modification of cellular proteins thought to be
involved in HCMV replication. We focused our investiga-
tion on phosphorylation of the cellular transcription factor
cAMP response element-binding protein (CREB) and his-
tone H3.
CREB is thought to directly or indirectly facilitate tran-
scription from the MIEP [18, 19] and other viral promoters
[20] during productive HCMV replication, and it has been
reported that phosphorylation of CREB at serine residue 133
(CREB-Ser133) by MSK1 is involved in promoting changes to
chromatin required for activation of the MIEP during HCMV
reactivation from latency [21]. In preliminary experiments, we
could not detect either total cellular CREB or CREB-Ser133
before 72 h p.i. using western blotting (data not shown). How-
ever, both proteins could only be detected at 72 h p.i. when we
Table 2. Viral replication assays
Expt Viral strain Compound ED50 (µM)
1 AD169 SB-734117 0.5
AD169 GCV 0.5
2 AD169 SB-734117 0.4
AD169-P53 SB-734117 1.3
3 AD169 SB-734117 1
Merlin(RCMV1111) SB-734117 2
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increased the amount of cell lysate assayed (see Methods).
Therefore, we used western blotting to assay total cellular
CREB and CREB-Ser133 phosphorylation in HCMV-infected
cells treated with either DMSO or SB-734117 at 72 h p.i.
(Fig. 5a). We observed a decrease in accumulation of CREB-
Ser133 and an increase in the accumulation of CREB in the
presence of SB-734117 (Fig. 5a, lane 5), compared to infected
cells treated with DMSO (Fig. 5a, lane 3). Analysis of relative
band intensities (Fig. 5b) indicated that there was approxi-
mately a two-fold decrease in CREB-Ser133 in infected cells
treated with SB-734117, compared to those treated with
DMSO and a modest increase in CREB. The two-fold decrease
in the accumulation of CREB-Ser133 in the presence of 1 µM
SB-734117 was consistent with the observed ED50 of 0.5–1 µM
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Fig. 3. Analysis of HCMV replication and protein production in infected HFF cells treated with DMSO or SB-734117 at the time of infec-
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and two- to four-fold decrease in production of immediate-
early HCMV protein production (Table 2 and Fig. 3). There-
fore, the effect of SB-734117 on HCMV replication correlated
with a loss of CREB-Ser133 phosphorylation. Similar observa-
tions were made when infected cells were treated with H89
(data not shown), indicating the AGC and CMCG kinase pro-
teins were involved in phosphorylation of CREB.
Phosphorylation of histone H3 by MSK1 or another kinase,
IKKa, is required for binding of transcription factors to DNA
in uninfected cells [22, 23]. We have previously demonstrated
that phosphorylation of histone H3 at serine residue 10
(H3S10p) by IKKa is associated with immediate-early protein
production during productive HCMV replication [17]. Also, it
has been demonstrated that H3S10 phosphorylation by MSK1
is associated with immediate-early gene expression during
reactivation of HCMV from latency [21]. We decided to assay
H3S10 phosphorylation in the presence of SB-734117. Using
Western blotting, we analysed accumulation of H3 and H3S10
phosphorylation in uninfected HFF cells (Fig. 5c, lane 1) and
AD169-infected HFF cells treated with either DMSO or SB-
734117 (Fig. 5c, lanes 2–4 and 5–7, respectively, at 24–72 h
p.i.). Similar levels of H3 were found in each sample; however,
over time we observed a decrease in H3S10p in infected cells
treated with SB-734117 to near undetectable levels, compared
to infected cells treated with DMSO. Therefore, inhibition of
H3S10 phosphorylation during productive HCMV replication
may have contributed to the anti-HCMV activity of SB-
734117. Similar results were found when infected cells were
treated with H89 (data not shown), indicating that AGC and
CMCG kinase proteins were involved in phosphorylation of
H3S10.
Phosphorylation of histone H3 at serine residue 28 (H3S28)
by MSK1 is also known to be associated with gene expres-
sion in uninfected cells [22]. We also used western blotting
to investigate H3S28 phosphorylation during HCMV repli-
cation. However, we could not detect H3S28p in uninfected
HFF cells, AD169-infected cells HFF treated with either
DMSO or SB-734117, or uninfected HFF cells treated with
either anisomycin, which can stimulate H3S28 phosphoryla-
tion, or phosphatase inhibitor okadaic acid, which can pre-
vent dephosphorylation of histones (data not shown).
Therefore, we concluded that inhibition of H3S28 phos-
phorylation did not contribute to the anti-HCMV activity
of SB-734117.
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Analysis of histone H3 post-translational
modifications in HCMV-infected cells
H3S10 phosphorylation by either MSK1 or IKKa is associated
with the presence of acetyl modifications of H3, including
acetylation (ac) of lysine 14 (H3K14ac) [24–26]. There is a
relationship during transcriptional activation between the
presence of H3S10p and H3K14ac and the association of
transcription factors with DNA [23, 27]. As the presence of
H3K14ac is associated with transcriptional activation in
HCMV-infected cells [28], H3K14ac may be required for
HCMV replication. We have previously demonstrated that,
during HCMV replication, inhibition or depletion of IKKa
leads to loss of total cellular H3S10 phosphorylation, but not
loss of total cellular H3K14ac [17]. Thus, we assayed whether
treatment of HCMV-infected cells by SB-734117 would lead
to loss of H3S10p or H3K14ac. We used Western blotting to
assay total cellular levels of H3, H3S10p and acetylation of H3
on a number of commonly studied H3 lysine residues includ-
ing K14 (H3K9ac, H3K14ac, H3K18ac, H3K27ac) in either
uninfected HFF cells (Fig. 5c, lane 1) or HFF cells infected
with HCMV and treated with either DMSO or SB-734117
(Fig. 5c, lanes 2–4 and 5–7, respectively). Treatment of
infected cells with SB-734117 had a slight effect [less than
twofold (data not shown)] on accumulation of H3K14ac and
no detectable effect on detection of H3K9ac, H3K18ac or
H3K27ac. Therefore, treatment of infected cells with SB-
734117 was associated with loss of total cellular H3S10p, but
not loss of the total cellular H3 acetylation modifications we
assayed, including H3K14ac.
The relationship between H3S10p and dimethylation (me2)
and trimethylation (me3) of H3 and H3 phosphorylation is
not well characterized, but it has been reported that, in a
murine model, there is a relationship between the presence
of H3S10p and the presence of H3K36me3 [29] and in
Drosophila melanogaster loss of the MSK1/2 homologue
JIL-1 results in loss of H3S10p, H3 acetylation and H3
methylation, including H3K36me3 [30]. Therefore, we
42
(a) (c)
(e)
(b)
CREB-Ser133
CREB
b-Actin
– –U
n
in
fe
c
te
d
D
M
S
O
S
B
-7
3
4
1
1
7
42
40
1 2 3 4
17
0 24 48
DMSO SB-734114
72 24 48 72 h p.i.
H3K9ac
H3K14ac
H3K18ac
H3K27ac
H3S10p
H3
b-Actin
17
17
17
17
17
48
1 2 3 4 5 6 7
17
(d)
0 24 48
DMSO SB-734114
72 24 48 72 h p.i.
H3K4me2
H3K27me2
H3K36me2
H3S10p
H3
b-Actin
17
17
17
17
48
17
17
17
17
17
17
48
1 2 3 4 5 6 7
0 24 48
DMSO SB-734114
72 24 48 72 h p.i.
H3K9me3
H3K4me3
H3K27me3
H3K36me3
H3S10p
H3
b-Actin
1 2 3 4 5 6 7
5
Protein Uninfected DMSO SB-734117
0.42
1.24
0.94
1.02
1.71
0.73
CREB-Ser133
CREB
Fig. 5. Inhibition of phosphorylation of cellular proteins by SB-734117. (a–c, lane 3) HFF cells were infected with AD169 at an m.o.i. of
1 and then treated with either 1 µM SB-734117 or the equivalent volume of DMSO (as indicated above each figure). Cell lysates were
prepared for Western blotting at (a) 72 h p.i. or (c–e) as indicated above the figure. Uninfected cells harvested at the time of infection
are shown as 0 h p.i. in (c–e). In (a), no lysate was analysed in lanes 2 and 4. Proteins recognized by the antibodies used are indicated
to the right of each figure. The positions of molecular mass markers (kDa) are indicated to the left of each figure. (b) Relative band
intensity of CREB and CREB-Ser133 bands relative to b-actin signal in the same lane in Fig. 5(a), as quantified using ImageJ. Band
intensities of 0–1, 1–2 and greater than 2 are highlighted in light grey, dark grey and black, respectively.
Khan et al., Journal of General Virology 2017;98:754–768
763
asked if loss of total cellular H3S10p in HCMV-infected
cells was associated with me2 and me3 modification of H3
lysine residues. Western blotting was used to assay the pres-
ence of H3 and H3S10p, as well as me2 (H3K4me2,
H3K27me2, H3K36me2) or me3 (H3K4me3, H3K9me3,
H3K27me3, H3K36me3) modifications of H3 in uninfected
HFF cells (lane 1, Fig. 5d, e, respectively) or HFF cells
infected with HCMV and treated with either DMSO or SB-
734117 (lanes 2–4 and 5–7, Fig. 5d, e, respectively). We
observed that SB-734117 had no effect on total cellular
accumulation of any me2 modification of H3 (Fig. 5d) or
accumulation of H3K4me3, H3K9me3 or H3K27me3
(Fig. 5e). However, we observed a near total loss of detect-
able H3K36me3 over time in infected cells treated with SB-
734117 (Fig. 5e), lane 7) compared to infected cells treated
with DMSO (Fig. 5e, lane 4). Similarly, a near total loss of
detectable H3K36me3 was observed in infected cells treated
with H89 (data not shown), suggesting that loss of
H3K36me3 is related to inhibition of AGC and CMCG
kinase proteins. Thus, inhibition of H3K36me3 was associ-
ated with loss of total cellular H3S10p and was likely the
result of inhibition of AGC and CMCG kinase proteins
inhibited by SB-734117. Loss of both total cellular H3S10p
and total cellular H3K36me3 may have contributed to the
anti-HCMV activity of SB-734117.
Investigation of HCMV MIEP transcriptional
activation
Loss of CREB and H3S10 phosphorylation (Fig. 5a–e) sug-
gested that SB-734117 acted by inhibiting activation of the
HCMV MIEP. However, our analysis of IE1 and IE2 gene
expression (Fig. 3d) indicated that transcription from the
MIEP was not obviously compromised in the presence of
SB-734117. To investigate this in more detail, we utilized
chromatin immunoprecipitation to assay the presence of
H3K14ac, a marker of MIEP transcriptional activation [28],
at the MIEP in the presence of either DMSO or SB-734117
(Fig. 6). The data showed no overt impact on H3K14ac at
the MIEP between 24 and 72 h p.i. in DMSO- or SB-
734117-treated cells. Indeed, we noted that SB-734117-
treated cells actually showed higher levels of H3K14ac at the
MIEP at late times p.i. when compared to control. There-
fore, in agreement with our analysis of IE1 and IE2 gene
expression (Fig. 3d), there was no obvious defect in MIEP
transcriptional activation in the presence of SB-734177.
Thus, the observed defects in HCMV immediate-early pro-
tein production (Figs 3, 4) could not be explained by defects
in transcription from the MIEP.
DISCUSSION
Our overall analysis of the chemotypes screened indicated
that each chemotype contained compounds with anti-
HCMV activity, however modest that anti-HCMV activity
may have been. As the structure of each compound in each
chemotype is known, structure–activity relationships
derived from our data could form the basis of future studies
in the discovery of compounds with anti-HCMV activity
from each chemotype.
Our survey of the PKIS kinase selectivity data argued that
several proteins from several kinase groups, alone or in
combination, were required for pp28 production. These
protein kinases include those from the STE (including
MAP4K4 and MNK), CAMK (including PRKD1, PRKD2
and PRKD3) and CMCG (including CLK2, HIPK1, HIPK4,
DYRK1A, DYRK1B, DYRK2) kinase groups. The function
of these protein kinases in productive HCMV replication is
unclear or unknown. Therefore, it is possible that our data
identified novel cellular factors required for productive
HCMV replication. However, the polypharmacology of the
compounds tested makes it difficult to identify specific kin-
ases required for productive HCMV replication. Thus, each
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of the aforementioned kinases will have to be tested individ-
ually to identify their roles in HCMV-infected cells. With
this information, these kinases could be exploited as novel
anti-HCMV drug targets.
We chose to pursue studies of SB-734117 as this compound
had one of the greatest negative effects on pp28 production
in our screen, with no obvious cytotoxic effects, and was an
effective inhibitor of a number of HCMV strains. Moreover,
the function of the AGC and CMCG kinase proteins inhib-
ited by SB-734117 in productive HCMV replication was
unknown or unclear.
SB-734117 was originally described as an inhibitor of
MSK1 [15]. However, like other MSK1 inhibitors [16], SB-
734117 displays polypharmacology and can inhibit several
kinases whose roles in productive HCMV replication are
unknown or unclear. Thus, to understand how SB-734117
inhibits HCMV replication, it will be necessary to under-
stand if a particular kinase, or a combination of kinase
proteins, is required for productive HCMV replication. A
truly selective inhibitor of MSK1 has yet to be found.
Structure–activity relationships involving SB-734117 and
other furazan benzimidazole compounds could be explored
to generate compounds with improved anti-HCMV activ-
ity and kinase selectivity. However, we could discern no
obvious relationship among inhibition of HCMV replica-
tion, kinase selectivity and the structures of compounds
within the furazan benzimidazole chemotype analysed here
due to the small number of furazan benzimidazole com-
pounds that returned low negative Z-scores in our screen
(data not shown). An improved compound related to SB-
734117 would have value as an anti-HCMV drug, as it
would have the potential to inhibit both productive
HCMV replication and reactivation of HCMV from
latency. In addition, based on our observations, an
improved compound should be as effective an inhibitor of
HCMV replication as GCV and be able to inhibit replica-
tion of GCV-resistant HCMV strains.
Perhaps the most intriguing observations we make concern
the modification of histone H3 in the presence of SB-
734117. Previous observations from our laboratory have
indicated that IKKa was required for H3S10 phosphoryla-
tion in AD169-infected HFF cells [17], which is consistent
with data presented elsewhere indicating that H3S10 is
a substrate of IKKa [24, 25, 31–33]. We note that inhibition
of IKKa results in loss of H3S10p early in HCMV replica-
tion (24 h p.i. onwards) [17], whereas treatment with SB-
734117 leads to a loss of H3S10p later in HCMV replication
(48–72 h p.i.). SB-734117 does not inhibit IKKa (Table S5).
Therefore, we propose that, in HCMV-infected cells, a
mechanism exists wherein IKKa does not phosphorylate
H3S10 during treatment with SB-734117. Conversely, kin-
ases inhibited by SB-734117 do not phosphorylate H3S10
when IKKa is inhibited or depleted. This mechanism may
ensure appropriate regulation of H3S10 phosphorylation
that is necessary for productive HCMV replication.
It has been reported that, in uninfected cells from humans
and mice, loss of H3S10p can lead to loss of H3K14ac [24–
26]. However, we did not observe loss of total cellular
H3K14ac upon treatment of HCMV-infected cells with SB-
734117 or in our previous study where inhibition or deple-
tion of IKKa resulted in loss of H3S10p [17]. We speculate,
as we have done previously [17], that an as yet unrecognized
mechanism exists in HCMV-infected cells that maintains
total H3K14ac when total H3S10p levels are lowered to near
undetectable levels.
We observed that treatment of HCMV-infected cells with
SB-734117 resulted in loss of H3K36me3. We have previ-
ously found that depletion of IKKa in HCMV-infected cells
leads to loss of H3S10p, but not H3K36me3 [17]. Therefore,
the loss of H3K36me3 in HCMV-infected cells is related to
loss of H3S10p during inhibition of AGC and CMCG kin-
ases, but not during inhibition of IKKa. This may be related
to regulation of H3S10 phosphorylation by different kinases,
as we discuss above. We propose that, as in mice and
Drosophila [29, 30], the presence of H3K36me3 in HCMV-
infected cells is related to the presence of H3S10p, poten-
tially via phosphorylation of H3 by MSK1. Alternatively,
there may be a substrate of kinase proteins inhibited by SB-
734117 whose phosphorylation directly or indirectly medi-
ates H3K36 tri-methylation.
Treatment of HCMV-infected cells with SB-734117
impacted on immediate-early protein production and
caused loss of total cellular levels of post-translational modi-
fication of cellular factors potentially involved in transacti-
vation of the HCMV MIEP. However, in the presence of
SB-734117, we did not find obvious defects in activation of
transcription from the HCMV MIEP or defects in immedi-
ate-early gene transcription. Therefore, the loss of total cel-
lular levels of CREB and H3S10 phosphorylation or
H3K36me3 had no direct impact on transcription from the
HCMV MIEP. This interpretation would be consistent with
previous studies that have shown that the deletion of CREB-
binding sites from the MIEP has little impact on productive
HCMV replication [21, 34]. During reactivation, it is
hypothesized the H3S10p is important as it drives the tran-
sition of the MIEP from a repressed to active promoter, a
mechanism also proposed for herpes simplex virus reactiva-
tion [35] Thus, during productive HCMV replication at
high m.o.i., where the MIEP is associated with active, not
repressed, chromatin very early p.i. [28], H3S10p may not
be essential for transcription. However, it remains possible
that H3S10p has a role in the release of early and late
HCMV promoters from repression as infection proceeds.
Thus, future challenges will include mapping of CREB,
H3S10p and H3K36me3 to viral and cellular promoters to
understand in more detail their possible involvement in
productive HCMV replication.
We propose that the greatest impact of SB-734117 on pro-
ductive HCMV replication is on production of IE proteins.
It will be important to investigate if SB-734117 impacts on
additional phosphorylation events that are required for
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production of both proteins. Post-translational modification
of both IE1 and IE2 is not yet completely characterized.
Thus, SB-734117 could directly or indirectly inhibit phos-
phorylation of these proteins, which leads to their loss. Fur-
ther investigation of IE protein production and the roles of
IE post-translational modification is required in order to
fully understand the mechanism of action of SB-734117
during productive HCMV replication.
METHODS
Compounds
The PIKS library (version 1) was supplied to the Institute of
Chemistry and Chemical Biology-Longwood at Harvard
Medical School by GlaxoSmithKline. SB-734117 was a kind
gift from GlaxoSmithKline. GCV was obtained from
SIGMA. H89 and heparan sulphate were obtained from Cal-
biochem. All drugs were resuspended in DMSO.
Cells and viruses
HFF cells (clone Hs29) were obtained from American Type
Culture Collection no. CRL-1684 and maintained in Dul-
becco’s modified Eagle’s medium (Gibco) containing 5%
(v/v) FBS (Gibco), as well as penicillin and streptomycin.
High-passage HCMV strain AD169 was a gift from Don
Coen (Harvard Medical School). Low-passage strain Merlin
R1111 (derived from BACmid pAL1111, which does not
express RL13 and UL128) [36] was a gift from Richard Stan-
ton (Cardiff University). GCV-resistant virus AD169-P53
was supplied by the National Institutes of Health (NIH)
AIDS Reagent Program.
High throughput screening
For screening of PKIS collection and analysis of screening
data, as well as characterization of compounds within the
PKIS collection, see Supplementary Material.
Viral yield reduction assays
Assays were performed essentially as described previously
[37]. HFF cells were plated at 5104 cells per well in 24-well
plates. After overnight incubation, cells were infected with
HCMV at an m.o.i. of 1. After virus adsorption for 1 h at
37

C, cells were washed and incubated with 0.5ml medium
containing DMSO or compounds at a range of concentra-
tions in duplicate. Plates were incubated for 4 days at 37

C.
Titres were determined by serial dilution of viral superna-
tant onto HFF monolayers that were covered in Dulbecco’s
modified Eagle’s medium containing 5% (v/v) FBS, 0.6%
methylcellulose and antibiotics. Cultures were incubated for
14 days, cells were stained with crystal violet and plaques
were counted. Data shown represent the mean value of
duplicate plaque counts. The final concentration of DMSO
in all samples was maintained at <1% (v/v).
MTT cytotoxicity assays
Assays were performed essentially as described previously
[37]. HFF cells were seeded at 1104 cells per well into 96-
well plates. After overnight incubation to allow cell
attachment, cells were treated for the time indicated in the
text at range of concentrations in duplicate. The highest
concentration of compound tested was 10 µM. Cell viability
was then determined with an MTT assay according to the
manufacturer’s instructions (GE Healthcare). Data shown
represent the mean value of duplicate readings. The final
concentration of DMSO in all samples was maintained at
<1% (v/v). As a positive control, in all experiments, a two-
fold dilution series of HFF cells starting at 1104 cells per
well was included. In each experiment, we found a linear
relationship between the number of cells per well and out-
put from the MTT assay (data not shown).
Western blotting
At time points indicated in the text, cells were washed once
with PBS and resuspended in 100 µl Laemmli buffer con-
taining 5% (v/v) b-mercaptoethanol. Proteins were
separated on 8 or 10% polyacrylamide gels. Typically, a vol-
ume of cell lysate corresponding to 1104HFF cells was
analysed, except when blotting for CREB or CREB-Ser133
when a volume of cell lysate corresponding to 5105HFF
cells was analysed. Antibodies used are listed in Supplemen-
tary Material. Relative band intensity (band intensity rela-
tive to b-actin signal in the same lane) was analysed using
ImageJ software, obtained from the NIH (USA).
RNA analysis and quantitative PCR
Quantitative PCR was performed using a SYBR green qPCR
kit (Qiagen) and analysed using the DDCt method to com-
pare DMSO- versus SB-734117-treated cells. Briefly, cDNA
was prepared from RNA extracted from infected cells at
time points indicated in the figure. cDNA and no RT con-
trols were amplified in technical duplicates from multiple
experiments using a constant primer in exon 3 (UL122-123)
and a primer from exon 4 (UL123) or exon 5 (UL122). Cel-
lular RNA was amplified using 18S RNA primers.
Exon 3, ACG AGA ACC CCG AGA AAG ATG; exon 4,
CGC CAG TGA ATT TCT CTT C; exon 5, CCG GGG
AGA GGA GTG TTA GT; 18S for, GTA ACC CGT TGA
ACC CCA; 18S rev, CCA TCC AAT CGG TAG TAG CG.
qPCR was performed using cycling conditions: 95

C (15 s)
and then 40 cycles of 94

C (15 s), 55

C (30 s) and 72

C
(30 s).
Chromatin immunoprecipitation
All procedures were performed essentially as previously
described [21]. Briefly, HFFs were fixed with 1% formalde-
hyde (10 min) and then enzymatically digested to fragment
DNA as described by the manufacturer (Pierce chromatin
preparation kit). DNA associated with histones was
immunoprecipitated with control serum (SIGMA) or anti-
acetyl-histone H3-lysine 14 (1 : 150 dilution of antibody;
see Supplementary Material). For detection of the HCMV
MIEP, DNA from disrupted nucleosomes was precipitated
and amplified by SYBR green qPCR kit (Qiagen) using 5¢-
TGG GAC TTT CCT ACT TGG-3¢ (sense) and 5¢-CCA
GGC GAT CTG ACG GTT-3¢ (anti-sense) primers.
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Specific immunoprecipitation of sequences was expressed
as enrichment from input.
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